Diagnosis and Treatment of CRMO in Pediatric Patients
CRMO in children should be diagnosed using whole-body MRI to identify multifocal bone lesions, treated first-line with NSAIDs (with rapid addition of bisphosphonates and/or TNF inhibitors for vertebral involvement), and monitored long-term even after treatment discontinuation. 1
Diagnosis
Clinical Presentation
CRMO presents with bone pain, often with an antalgic gait (45% of cases), local inflammation (30%), and fever/fatigue (26%). A critical pitfall: 58% present with unifocal symptoms clinically, but 81% actually have multifocal disease on imaging 2. The most commonly affected sites are the femur, tibia, pelvis, and spine (each >30% of cases) 2.
Diagnostic Workup
- Whole-body MRI is the imaging modality of choice 1 - it identifies multifocal lesions that may not be clinically apparent and helps distinguish CRMO from infection or malignancy
- Plain radiographs are unremarkable in 35% of cases; when positive, they show periosteal reaction/sclerosis (23%) or lytic lesions (22%) 2
- MRI findings include bone marrow edema (72%), periosteal reaction (23%), and osteitis (19%) 2
- CRMO remains a diagnosis of exclusion - there are no specific biomarkers 1
Avoiding Unnecessary Biopsies
The Jansson criteria can identify 80% of patients who could be spared bone biopsy 2. This is particularly important given the average diagnostic delay of 6 months 2. The Jansson criteria is more sensitive than the Bristol criteria (OR 3.94, P < 0.001) 2.
Treatment Algorithm
First-Line Treatment
Vertebral Involvement - Requires Aggressive Treatment
If vertebral lesions are present, immediately escalate to bisphosphonates and/or TNF inhibitors 1. This is critical because vertebral involvement carries higher risk for skeletal deformities, compromised joint functionality, and vertebral fractures 4.
Second-Line Treatment (for inadequate response to NSAIDs)
- Conventional DMARDs (e.g., methotrexate)
- Biologic DMARDs (TNF inhibitors like infliximab)
- Bisphosphonates (e.g., pamidronate) 1, 5
Treatment Duration and Monitoring
Long-term monitoring is essential, including follow-up after treatment discontinuation, as CRMO is a chronic disease with relapsing-remitting patterns 1. Persistent inflammation can cause irreversible skeletal complications including physeal damage and limb length discrepancy 6.
Key Clinical Pitfalls
Misdiagnosis as infection or malignancy: Pediatric orthopedic surgeons most commonly consider infection (34%) and neoplasm (21%) initially 2. Avoid unnecessary antibiotics by recognizing the sterile nature of CRMO.
Missing multifocal disease: Always obtain whole-body imaging even when symptoms appear unifocal 1, 2.
Delayed treatment of vertebral involvement: This requires immediate escalation to prevent irreversible complications 1.
Associated conditions: Be alert for palmoplantar pustulosis, psoriasis, inflammatory bowel disease, and other autoinflammatory features 5, 7.